AMLX
Amylyx Pharmaceuticals, Inc.Company with tickers: AMLX
CIK
1658551
CUSIP
03237H101
Shares Outstanding
111,186,317
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $27,610,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-43,779,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-41,284,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $-0.37 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | $-0.37 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |